摘要目的 观察阿帕替尼联合奥沙利铂+替吉奥治疗晚期胃癌的临床疗效.方法 选取2015年3月至2017年3月宝鸡市中心医院收治的晚期胃癌患者150例,根据随机数字表法将入选患者分为研究组(阿帕替尼联合奥沙利铂+替吉奥)与对照组(奥沙利铂+替吉奥),各75例.比较两组患者的近期疗效和不良反应.结果 研究组的有效率(46.7%比25.3%)与控制率(76.0%比48.0%)均高于对照组,差异均有统计学意义(均P<0.05);两组骨髓抑制、消化道反应、乏力及口腔溃疡等并发症的发生率比较,差异均无统计学意义(均P>0.05);两组高血压、蛋白尿及手足综合征等并发症的发生率比较,研究组均高于对照组,差异均有统计学意义(均P<0.05),但均为Ⅰ~Ⅱ度,患者可以耐受.结论 阿帕替尼联合奥沙利铂+替吉奥作为晚期胃癌的化疗方案,可能具有较好的疗效.

abstractsObjective To investigate the clinical efficacy of apapatinib-targeted therapy combined with oxaliplatin and tiggio for treatment of gastric cancer. Methods A total of 150 patients with advanced gastric cancer were enrolled from March 2015 to March 2017. According to the random number table method, the patients were divided into the study group (apocitinib combined with oxaliplatin+tiggio) and the control group (oxaliplatin + tiggio), 75 cases each. The recent treatment effects and adverse reactions were compared between the two groups. Results The objective response rate (46.7 % vs. 25.3 %) and disease control rate (76.0 % vs.48.0 %)in the study group and the control group were statistically significant(all P <0.05).There were no statistical differences in the incidence of complications such as myelosuppression, digestive tract reaction, fatigue and oral ulcer between the two groups (all P > 0.05). The incidence of complications such as hypertension, proteinuria and hand-foot syndrome in the study group was higher than those in the control group (all P < 0.05), but it was in a state of grade Ⅰ~Ⅱ and tolerance. Conclusion Apotiphene combined with oxaliplatin and tiggio as a chemotherapy regimen for advanced gastric cancer may have a better effect.